Pinealon

At a glance

Standard Protocol

Alternative Titration 1: Extended Protocol (Goal: general CNS oxidative defense restoration with minimized stimulation side effects; preferred for sensitive subjects)

Alternative Titration 2: 30-Day Graduated Protocol (Goal: sensitive subjects, first cycle, or gentlest possible pan-CNS bioregulator introduction)

Alternative Titration 3: Neuroprotection Pre-Loading Protocol (Goal: CNS oxidative defense pre-loading before planned surgical anesthesia, chemotherapy, or radiation therapy with known CNS toxicity)

Alternative Titration 4: Sleep Architecture Restoration Protocol (Goal: circadian rhythm normalization and sleep quality improvement in subjects with age-related circadian dysregulation; run concurrent with DSIP at bedtime for additive effect)

Alternative Titration 5: Parkinson's Disease Neuroprotection Protocol (Goal: substantia nigra and basal ganglia oxidative defense support; requires neurologist supervision; concurrent with Cortagen for complete CNS coverage)

Bioregulator protocols are often cycle-based because the claim is organ-system signaling rather than acute symptom control. The logic should be organ-specific labs, medical context, and humility about older or vendor-derived evidence. Entry context: target (CNS); route Subcutaneous; timing Morning. Unapproved or source-dataset dosing tables are hypotheses, not recommendations.

• Mild headache on cycle initiation: the most commonly reported adverse effect; occurs in a minority of subjects in the first 1-3 days; related to the shift in CNS metabolic and oxidative activity as the bioregulator effect begins; typically resolves without intervention.
• Increased dream vividness: pineal and circadian circuitry interaction produces more active REM architecture in some subjects; similar to Epithalon but typically milder.
• Mild morning energy increase: the intended cortical activation effect of morning dosing; experienced as desired enhanced alertness by most subjects; can be overstimulating in a small minority.
• Mild transient anxiety (rare): uncommon; a small subset of subjects reports mild anxious feelings in the first days of a new cycle; typically resolves after day 3-5 as CNS adaptation occurs.
• Injection site mild reaction: standard subcutaneous peptide response; minimal.
• No serious neurological adverse events documented in the Khavinson literature at standard protocol doses: the CNS safety profile across aging and neurological disease research populations is clean.
• Unknown interaction profile with modern CNS pharmacology (novel antidepressants, antipsychotics, cognitive enhancers): Pinealon's research predates modern psychopharmacology; formal interaction data does not exist.

• Active CNS infections (meningitis, viral encephalitis, brain abscess): exogenous CNS bioregulator activity modulating neuronal and microglial gene programs during active brain infection could alter the CNS immune response in unpredictable ways.
• Uncontrolled seizure disorder: pan-CNS gene program modulation affecting neuronal excitability thresholds and mitochondrial energy generation in epileptic brain tissue has not been characterized; medical supervision required.
• Active intracranial malignancy: Pinealon's pan-CNS neurotrophic and cell survival-supporting mechanisms have not been evaluated in brain tumor tissue that may express CNS cell surface receptors.
• Concurrent use with narrow therapeutic index CNS drugs (phenytoin, carbamazepine, lithium, clozapine) where CNS state changes require stable pharmacological conditions: not a documented pharmacokinetic interaction but a clinical management consideration.
• Known hypersensitivity to Pinealon (Glu-Asp-Arg tripeptide) or formulation excipients.
• Pregnancy: CNS gene program modulation during fetal brain development has not been evaluated.
• Active acute stroke (within 72 hours) without medical supervision: while animal data suggests Pinealon may be neuroprotective post-stroke, the timing, dosing, and interaction with thrombolytic or thrombectomy therapy in acute stroke management requires clinical supervision.

Synergistic / related

• https://the source dataset.com/peptide-codex.php
• https://www.fda.gov/drugs/guidance-compliance-regulatory-information/human-drug-compounding
• https://pubmed.ncbi.nlm.nih.gov/?term=Pinealon